Ibrutinib effect in acquired von Willebrand syndrome secondary to Waldenström macroglobulinemia

1. Hivert, B, Caron, C, Petit, S, et al. Clinical and prognostic implications of low or high level of von Willebrand factor in patients with Waldenstrom macroglobulinemia. Blood 2012; 120: 3214–3221.
Google Scholar | Crossref | Medline2. Castillo, JJ, Gustine, JN, Meid, K, et al. Low levels of von Willebrand markers associate with high serum IgM levels and improve with response to therapy, in patients with Waldenström macroglobulinaemia. Br J Haematol 2019; 184: 1011–1014.
Google Scholar | Crossref | Medline3. Dicke, C, Schneppenheim, S, Holstein, K, et al. Distinct mechanisms account for acquired von Willebrand syndrome in plasma cell dyscrasias. Ann Hematol 2016; 95: 945–957.
Google Scholar | Crossref | Medline4. Kapoor, P, Ansell, SM, Fonseca, R, et al. Diagnosis and management of Waldenström macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) guidelines 2016. JAMA Oncol 2017; 3: 1257–1265.
Google Scholar | Crossref | Medline5. Tiede, A, Rand, JH, Budde, U, et al. How I treat the acquired von Willebrand syndrome. Blood 2011; 117: 6777–6785.
Google Scholar | Crossref | Medline | ISI6. Mayerhofer, M, Haushofer, A, Kyrle, PA, et al. Mechanisms underlying acquired von Willebrand syndrome associated with an IgM paraprotein. Eur J Clin Invest 2009; 39: 833–836.
Google Scholar | Crossref | Medline7. Gertz, MA. Waldenström macroglobulinemia: 2019 update on diagnosis, risk stratification, and management. Am J Hematol 2019; 94: 266–276.
Google Scholar | Crossref | Medline8. Coucke, L, Marcelis, L, Deeren, D, et al. Lymphoplasmacytic lymphoma exposed by haemoptysis and acquired von Willebrand syndrome. Blood Coagul Fibrinolysis 2014; 25: 395–397.
Google Scholar | Crossref | Medline9. Federici, AB, Rand, JH, Bucciarelli, P, et al. Acquired von Willebrand syndrome: data from an international registry. Thromb Haemost 2000; 84: 345–349.
Google Scholar | Crossref | Medline | ISI10. Treon, SP, Ioakimidis, L, Soumerai, JD, et al. Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180. J Clin Oncol 2009; 27: 3830–3835.
Google Scholar | Crossref | Medline | ISI11. Ghobrial, IM, Xie, W, Padmanabhan, S, et al. Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström macroglobulinemia. Am J Hematol 2010; 85: 670–674.
Google Scholar | Crossref | Medline12. Dimopoulos, MA, Tedeschi, A, Trotman, J, et al. Phase 3 trial of ibrutinib plus rituximab in Waldenstrom’s macroglobulinemia. N Engl J Med 2018; 378: 2399–2410.
Google Scholar | Crossref | Medline13. Treon, SP, Tripsas, CK, Meid, K, et al. Ibrutinib in previously treated Waldenström’s macroglobulinemia. N Engl J Med 2015; 372: 1430–1440.
Google Scholar | Crossref | Medline | ISI14. Yosef, A, Touloukian, EZ, Nambudiri, VE. Ibrutinib in the management of Waldenstrom macroglobulinemia. J Oncol Pharm Pract 2019; 25: 434–441.
Google Scholar | SAGE Journals | ISI15. Shatzel, JJ, Olson, SR, Tao, DL, et al. Ibrutinib associated bleeding: pathogenesis, management and risk reduction strategies. J Thromb Haemost 2017; 15: 835–847.
Google Scholar | Crossref | Medline16. Wang, ML, Blum, KA, Martin, P, et al. Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood 2015; 126: 739–745.
Google Scholar | Crossref | Medline | ISI17. Ojeda-Uribe, M, Rimelen, V, Marzullo, C. Good profile of efficacy/tolerance of bortezomib or idelalisib in Waldenström macroglobulinemia associated with acquired von Willebrand syndrome. J Blood Med 2020; 11: 67–72.
Google Scholar | Crossref | Medline18. Hampel, PJ, Call, TG, Rabe, KG, et al. Disease flare during temporary interruption of ibrutinib therapy in patients with chronic lymphocytic leukemia. Oncologist 2020; 25: 974–980.
Google Scholar | Crossref | Medline

留言 (0)

沒有登入
gif